The psilocybin GAD oral-solution trial reports positive preliminary tolerability and signal of anxiety reduction, prompting a follow-on Phase 2 announcement within 6 months.

A trial testing liquid psilocybin (the active compound in 'magic mushrooms') for generalized anxiety disorder (GAD) — a condition where people feel persistent, hard-to-control worry — is expected to report that the drug was well-tolerated and showed early signs of reducing anxiety. That kind of positive early result typically gives researchers and funders enough confidence to launch a bigger, more rigorous Phase 2 trial.

GAD is a natural expansion for psilocybin's anxiolytic profile. Early safety wins fund the next phase. Every indication opened helps suffering patients.